A Modified YpTNM Staging System-Development and External Validation of a Nomogram Predicting the Overall Survival of Gastric Cancer Patients Received Neoadjuvant Chemotherapy

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Apr 8

PMID 32256112

Citations 7

Authors

Ziyu Li

Qiyan Xiao

Yinkui Wang

Wei Wang

Shuangxi Li

Fei Shan

Zhiwei Zhou

Jiafu Ji

Affiliations

Soon will be listed here.

Abstract

Purpose: Neoadjuvant chemotherapy is now widely used in gastric cancer patients. However, the current 8th ypTNM staging system is developed based on patients with less extensive lymph node dissection and the predictive value is relatively limited. In this study, we aim to develop and validate a nomogram that predicts overall survival in gastric cancer patients received neoadjuvant chemotherapy.

Patients And Methods: From January, 2007 to December, 2014, 471 patients receiving neoadjuvant chemotherapy at our center were enrolled in the study. Based on the Cox proportional hazard model, a nomogram was developed from them and then an external validation was conducted on a cohort of 239 patients from another cancer center.

Results: The overall survival (OS) rates of 1 year and 3 years were 90.0% and 64.1%, respectively. Body mass index category, tumor location, T stage and N stage were independent prognostic factors for the survival outcome. The C-index of the model was 0.74 in the development cohort and 0.69 in the validation cohort. Our nomogram also showed good calibration in both cohorts.

Conclusion: We developed and validated a nomogram to predict the 1- and 3-year OS of patients who received neoadjuvant chemotherapy and radical gastrectomy with D2 lymph node dissection. This nomogram predicts survival more accurately than the AJCC TNM staging system, which is the current golden standard.

Citing Articles

Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer.

Wang Y, Feng L, Wang G, Yu P, Guo C, Cai B World J Gastrointest Surg. 2024; 16(10):3224-3238.

PMID: 39575280 PMC: 11577390. DOI: 10.4240/wjgs.v16.i10.3224.

Development and evaluation of the Newstage system: integrating tumor regression grade and lymph node status for improved prognostication in neoadjuvant treatment of gastric cancer.

Chen M, Yu S, Chen C, Liang J, Zhou D World J Surg Oncol. 2024; 22(1):16.

PMID: 38195570 PMC: 10777530. DOI: 10.1186/s12957-023-03291-4.

Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer.

Wang G, Tan Y, Jiang Y, Liu J, Su Y, Sun Z Risk Manag Healthc Policy. 2023; 16:1259-1271.

PMID: 37456825 PMC: 10348377. DOI: 10.2147/RMHP.S413052.

Revisiting the 8th AJCC system for gastric cancer: A review on validations, nomograms, lymph nodes impact, and proposed modifications.

Mranda G, Xue Y, Zhou X, Yu W, Wei T, Xiang Z Ann Med Surg (Lond). 2022; 75:103411.

PMID: 35386808 PMC: 8977912. DOI: 10.1016/j.amsu.2022.103411.

Anatomic Subsites and Prognosis of Gastric Signet Ring Cell Carcinoma: A SEER Population-Based 1 : 1 Propensity-Matched Study.

Xie Y, Song X, Dong W, Jin H, Ni Z, Li X Biomed Res Int. 2022; 2022:1565207.

PMID: 35141330 PMC: 8818421. DOI: 10.1155/2022/1565207.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

Kojima N, Yonemura Y, Bando E, Morimoto K, Kawamura T, Yun H . Optimal extent of lymph node dissection for T1 gastric cancer, with special reference to the distribution of micrometastasis, and accuracy of preoperative diagnosis for wall invasion. Hepatogastroenterology. 2008; 55(84):1112-7. View

Petrelli F, Ghidini M, Barni S, Steccanella F, Sgroi G, Passalacqua R . Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. Ann Surg Oncol. 2017; 24(9):2655-2668. DOI: 10.1245/s10434-017-5832-4. View

Biagi J, Raphael M, Mackillop W, Kong W, King W, Booth C . Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011; 305(22):2335-42. DOI: 10.1001/jama.2011.749. View

Chou H, Kuo C, Hsu J, Chen T, Lin C, Tseng J . Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis. Am J Surg. 2012; 205(6):623-30. DOI: 10.1016/j.amjsurg.2012.04.014. View

Eom B, Kim S, Kim J, Yoon H, Kim M, Nam B . Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis. J Gastric Cancer. 2018; 18(1):69-81. PMC: 5881012. DOI: 10.5230/jgc.2018.18.e9. View

Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y . Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2012; 16(1):1-27. PMC: 3549249. DOI: 10.1007/s10120-012-0163-4. View

Chua T, Merrett N . Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer. 2011; 130(12):2845-56. DOI: 10.1002/ijc.26292. View

10.

Liu Z, Feng F, Guo M, Liu S, Zheng G, Xu G . Distal gastrectomy versus total gastrectomy for distal gastric cancer. Medicine (Baltimore). 2017; 96(5):e6003. PMC: 5293459. DOI: 10.1097/MD.0000000000006003. View

11.

Talamonti M, Kim S, Yao K, Wayne J, Feinglass J, Bennett C . Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003; 134(4):720-7. DOI: 10.1016/s0039-6060(03)00337-4. View

12.

Sun Y, Zhang Y, Wu X, Lin H, Lu X, Huang Y . Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model. J Surg Oncol. 2017; 117(4):737-744. DOI: 10.1002/jso.24907. View

13.

Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D . Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014; 40(5):584-591. DOI: 10.1016/j.ejso.2013.09.020. View

14.

Wilke H, Preusser P, Fink U, Gunzer U, Meyer H, Meyer J . Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol. 1989; 7(9):1318-26. DOI: 10.1200/JCO.1989.7.9.1318. View

15.

Ogura K, Fujiwara T, Yasunaga H, Matsui H, Jeon D, Cho W . Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study. Cancer. 2015; 121(21):3844-52. PMC: 5034754. DOI: 10.1002/cncr.29575. View

16.

Bickenbach K, Denton B, Gonen M, Brennan M, Coit D, Strong V . Impact of obesity on perioperative complications and long-term survival of patients with gastric cancer. Ann Surg Oncol. 2012; 20(3):780-7. DOI: 10.1245/s10434-012-2653-3. View

17.

Ahn H, Jeong S, Son Y, Lee H, Im S, Bang Y . Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. Br J Surg. 2014; 101(12):1560-5. DOI: 10.1002/bjs.9632. View

18.

Han D, Suh Y, Kong S, Lee H, Choi Y, Aikou S . Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012; 30(31):3834-40. DOI: 10.1200/JCO.2012.41.8343. View

19.

Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S . Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018; 51:120-127. DOI: 10.1016/j.ijsu.2018.01.008. View

20.

Ahn H, Lee H, Hahn S, Kim W, Lee K, Sano T . Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010; 116(24):5592-8. DOI: 10.1002/cncr.25550. View